The primary goal of precision medicine is to maximize the benefit-risk relationships for individual patients by delivering the right drug to the right patient at the right dose. To achieve this goal, it has become increasingly important to assess gene-drug interactions (GDIs) in clinical settings. The U.S. Food and Drug Administration (FDA) periodically updates the table of pharmacogenetic/genomic (PGx) biomarkers, including germline or somatic gene variants and functional deficiencies, in drug labeling on their website (https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling). These PGx biomarkers can play an important role in identifying responders and non-responders to medications, optimizing drug doses, and avoiding adverse events, due to the results of GDIs. This presentation will highlight whether the labeling language of these PGx biomarkers can be actionable in clinical practice, particularly focusing on the comparison between two major PGx biomarkers in the FDA-PGx table, oncology molecular targets and drug-metabolizing enzymes and transporters. The presentation will also provide some perspective on how precision medicine is currently being implemented at the bedside in the U.S..